Use of the investigational drug efruxifermin did not significantly reduce fibrosis in patients with compensated cirrhosis ...

AMSTERDAM — A once daily, 50 mg dose of efruxifermin reduced fibrosis at 96 weeks in patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH) compared with ...

Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment landscape for patients with metabolic dysfunction-associated steatohepatitis ...

Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis ...

The publication reports results from the 96-week SYMMETRY study evaluating the efficacy and safety of Akero’s lead FGF21 analog efruxifermin (EFX), in participants with biopsy-confirmed compensated ...

We recently published an article titled Billionaire Nicholas J. Pritzker’s 8 Stocks with Huge Upside Potential. In this article, we are going to take a look at where Madrigal Pharmaceuticals, Inc.

According to a new major clinical trial known as the ESSENCE trial, semaglutide—better known as Ozempic when used for Type 2 ...

Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today reported financial ...

Understand how semaglutide shows strong benefits in MASH treatment, improving liver health and reducing weight.

A promising target for rare liver cancer, a functional cure for multiple myeloma — and support for people with ovarian cancer.

Roche is rolling out a new diagnostic test to help assess hidden liver fibrosis in patients showing signs of metabolic ...